Peter Block, MD, FACC, and Deepak L. Bhatt, MD, MPH, FACC, discuss the Thursday meeting highlights from TCT 2015, including the SAPIEN 3 trial and the BRAVO 3 trial. View full TCT 2015 meeting coverage at ACC.org/TCT and watch all the video coverage on ACC’s YouTube page.
“Biomedical innovation represents the best and enables the worst of our health care system,” began Alan Weil, editor-in-chief of Health Affairs, at the opening of the publication’s briefing on a recent issue, which featured panel discussions with featured authors. A majority of the authors’ findings were overwhelmingly positive for the future of medicine, including one study which showed the evolution of biotechnology and its impact on health care over the past 35 years. Ronald A. Evens, MD, author of the study, remarked “biotech molecules have dramatically altered heath care for many unmet medical needs across all medical disciplines.”
During the panel on medical devices, I presented the recently published Health Affairs paper, “Transcatheter Valve Therapy Registry Is A Model For Medical Device Innovation And Surveillance,” showing that advances in biotechnology go beyond the molecules to include the actual systems that track and record who receives biotech devices and how they respond to them. In the paper, we took a close look at the STS/ACC TVT Registry, which is a model of collaboration among professional societies, the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, hospitals, patients, and the medical device industry. Continue reading
See ACC video coverage of the hottest topics from opening day of ACC.14:
“…and where would I hear the murmur?” – Anonymous participant at a recent Championing Care meeting
All of us, having alternately taught and been taught all of our lives, are educators, reveling in that never-ending cycle of falling behind and catching up again, reproduced the world over.
Tactically, our post-graduate continuing medical education has been structured as “onion-skinning,” our substantial pre-existing knowledge base repetitively veneered with a thin layer of highly specific new content applied intermittently. In practical terms, a group of interventionists come together and receive late-breaking information about interventional cardiology, echocardiographers gaining similar information regarding their imaging modality, that content being tailored specifically to what is a highly select audience, a horizontally homogenous group consuming specific information updates in a periodic fashion. Continue reading
This post was authored by David R. Holmes, Jr., MD, MACC, a past president of the ACC.
As the number of patients undergoing transcatheter aortic valve replacement (TAVR) procedures continues to grow in the U.S., the STS/ACC TVT Registry continues to be a resource to track patient safety and real-world TAVR outcomes.
This past weekend at Society of Thoracic Surgeons’ Annual Meeting, a report using data from the TVT Registry and the STS Adult Cardiac Surgery Database was presented and showed that since TAVR has been commercially available in the U.S., low- and intermediate-risk surgical aortic valve replacement (SAVR) volumes have continued to increase. Further, while the volume of SAVR has declined slightly in high-risk cases, combined TAVR and SAVR volumes have risen (from 4,249 cases in 2011 to 8,082 in 2012), and overall associated mortality has declined in this cohort, from 8.9 percent in 2011 to 7.0 percent in 2012. Continue reading
This post was authored by Xiushui (Mike) Ren, MD, affiliate member of the ACC, reporting live for CardioSource.org.
The Transcatheter Valve Therapeutics (TVT) 2013 conference kicked-off yesterday with “The Annual Mad Dash” presentation by Martin Leon, MD, FACC, who summarized the past year of transcatheter aortic valve replacement (TAVR) research in an impressive 20 minutes. According to Leon, there were a total of 835 TAVR manuscripts published in 2012 and 2013. Highlights included: Continue reading
This post is authored by John S. Rumsfeld, MD, PhD, FACC, chief science officer of the NCDR.
The NCDR’s annual conference (NCDR.13) started today and is already off to a great start. Over 950 registry professionals, cardiovascular physicians and administrators are in attendance, and the meeting opened with a great keynote presentation about excellence in cardiovascular care and the role of the NCDR given by Martha Radford, MD, FACC, director of clinical quality and safety at NYU Hospital Center.
In response to physician and health care administrator’s growing interest in the NCDR, we’ve added a MD/Administrator track to NCDR.13, which includes a series of workshops specifically designed for their needs. Health care in the U.S. is changing dramatically and cardiovascular professionals face a future that will include more public reporting of quality measures, increased needs to demonstrate performance improvement, and an increased focus on outcomes. The NCDR can directly help physicians and administrators with these, so this is a major focus for the NCDR programs going forward, starting with the NCDR.13 meeting.
Meanwhile, NCDR research will be featured throughout ACC.13. Twenty-two abstracts, including oral and poster presentations will feature NCDR research. Several of the topics discussed at the NCDR.13 will be further fleshed out in educational sessions as well, including sessions focused on the use of registry data for MOC purposes, international registry lessons learned, TAVR research and more.
Congratulation to Jonathan Hsu, MD author of the poster “Inappropriate Oral Anticoagulant Use in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Program,” which is being recognized as a Best of Poster and Best FIT Poster at ACC.13. The poster will be on display Monday, March 11th from 9:45-10:30 a.m. in Poster Sessions, Expo North.
For the complete guide to NCDR abstracts at ACC.13, visit NCDR.com/ACC13 or stop by ACC Central during Expo hours.